Author

Moncef Boukerrou

Institution: Bayer (United States)

Observed institution: Bayer (United States)

OpenAlex ID: A5073701673

PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol

2021 · Guy Young, Mark T Reding, et al. · Blood · 1

Works count: 1

Citation count: 1

H-index: 1

I10-index: